ATAI Life Sciences & Compass Pathways Co-Founder Christian Angermayer joins the show to talk about the roadblocks to getting psychedelics legal in the US and the best way to effectively treat mental health with them. Christian has been making waves recently after appearing on Joe Rogan, and has the backing of Peter Thiel. We've been talking alot about the potential of psychedelics in the past year, and after the FDA's recent disappointing decision... Christian tells us why it may not be all bad news. Sam handles the interview with Christian and then Derek hops in with Sam to talk about their interest in this investment.

The views and opinions expressed by Christian Angermayer in this episode are his own and do not necessarily represent those of atai Life Sciences.

Discussed:

• Dr. Nutt's "Drug Harm" Chart
• ATAI Investor Relations
• Compass Pathways Investor Relations
• Christian Angermayer's Substack
• ILAB 294: Matthew "Whiz" Buckley on Flying in Top Gun, Trading Options & Taking Psychedelics

Where we are:

• Johnny FD – Kyiv, Ukraine / IG @johnnyfdj
• Sam Marks - Bangkok, Thailand / IG @sammarks12
• Derek – Los Angeles, USA / IG @DerekRadio

Sponsor:

• Shopify
  Shopify helps you sell EVERYWHERE. From their all-in-one ecommerce platform, to their in-person POS system–wherever and whatever you’re selling, Shopify’s got you covered. Sign up for a $1 per month trial period now at Shopify.com/ilab

• 
  

• ILAB Patreon
  Join the Invest Like a Boss Patreon now and get tons of bonus content, including additional episodes, full quarterly updates including account screenshots and more for as low as $5/month at Patreon.com/InvestLikeaBoss

Time Stamp:

• 00:21 - Sam/Derek Intro
• 06:09 - Interview with Christian Begins
• 32:00 - Why FDA Approval is Taking So Long
• 57:07 - The State of Psychedelic Stocks
• 01:08:13 - Sam/Derek Outro - Would They Invest

If you enjoyed this episode, do us a favor and share it! If you haven't already, please take a minute to leave us a 5-star review on Apple Podcasts and Spotify.

Copyright 2024. All rights reserved. Read our disclaimer here.